Month: September 2016

Rowe Researcher: Understanding the Role of SR-B1

Posted on by

Understanding the Role of SR-B1 in Lipid Metabolism and Inflammation

Summer 2016

Investigators: Christopher Blesso, Christina Jiang

SR-B1 is an HDL receptor that has a role in cholesterol exchange and the initiation of intracellular signaling cascades involved in lipid metabolism. SR-B1 is highly expressed in the liver, but its function has not been fully determined in adipocytes, which is the aim of this project. Cholesterol imbalance can result in disease states such as atherosclerosis, so the study of this HDL receptor can be implicated in disease prevention.

The aim of the research was to perform successful knockdown in 3T3-L1 adipocytes by using siRNA (scramble, cyclophilin, SR-B1); determine gene expression of SR-B1 and cyclophilin to confirm knockdown; determine inflammatory response of adipose by introducing LPS or macrophage-conditioned media to cells. After treating the cells with the appropriate reagents, RNA was isolated, cDNA was synthesized, and PCR was conducted to confirm knockdown. There was a 40% knockdown in cyclophilin when treated with cyclophilin siRNA and insignificant knockdown with SR-B1 knockdown. There is about a 60-70% knockdown of SR-B1 in adipocytes treated with SR-B1 siRNA, indicating that the knockdown was successful. In the presence of macrophages, there is about a 40% knockdown of SR-B1. In the presence of LPS, there is also about a 40% knockdown of SR-B1. These successful gene knockdowns provide evidence to continue on with the experiment.

Rowe Researcher: Drug Treatment for Depression

Posted on by
Shanicka Reynolds
Shanicka Reynolds presenting her research at Frontiers in Undergraduate Research

 

Drug Treatment for Depression: Deprenyl’s Effect on Motivation, Effort and Behavior

2015-2016

Investigator: Shanicka Reynolds

Depression is more than a feeling of sadness. It can progress into a disabling disease that degrades mental, physical, and social health. One of the most debilitating symptoms of depression is a decrease in motivational behavior. Motivational symptoms such as fatigue and anergia are difficult to treat and many of the existing antidepressants do not effectively treat motivational symptoms. This project will focus on the MAO-B inhibitor drug, deprenyl. The goal is to provide a more detailed characterization of the motivational effects of deprenyl through experimentation. Successful increase of motivational behavior using deprenyl will not only benefit patients suffering from depression, but will help patients of various disorders such as Parkinson’s where depression can be a side effect of their disease.